Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma

AG Sacco, EE Cohen - Journal of clinical oncology, 2015 - ascopubs.org
This review highlights the evidence-based data to support current best management
practices for patients with recurrent and/or metastatic (R/M) head and neck squamous cell …

[HTML][HTML] Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma

P Bossi, C Resteghini, N Paielli, L Licitra, S Pilotti… - Oncotarget, 2016 - ncbi.nlm.nih.gov
EGFR is an extensively studied biomarker in head and neck squamous cell carcinoma
(HNSCC). In this review, we discuss the prognostic and predictive role of EGFR in HNSCC …

[HTML][HTML] EGFR Mutations in Head and Neck Squamous Cell Carcinoma

S Nair, JA Bonner, M Bredel - International Journal of Molecular Sciences, 2022 - mdpi.com
EGFR is a prototypical receptor tyrosine kinase that is overexpressed in multiple cancers
including head and neck squamous cell carcinoma (HNSCC). The standard of care for …

Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism

F Braig, M Kriegs, M Voigtlaender, B Habel, T Grob… - Cancer research, 2017 - AACR
Head and neck squamous cell carcinomas (HNSCC) exhibiting resistance to the EGFR-
targeting drug cetuximab poses a challenge to their effective clinical management. Here, we …

Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: a review of the literature

P Bossi, S Alfieri, P Strojan, RP Takes, F López… - Critical reviews in …, 2019 - Elsevier
The pattern of clinical behaviour and response to treatment of recurrent and/or metastatic
head and neck squamous cell carcinoma is heterogeneous. Treatment strategies that can …

[HTML][HTML] Therapeutic strategies of different HPV status in head and neck squamous cell carcinoma

Y Sun, Z Wang, S Qiu, R Wang - International Journal of Biological …, 2021 - ncbi.nlm.nih.gov
Head and neck squamous cell carcinoma (HNSCC) is the 9 th most common malignant
tumor in the world. Based on the etiology, HNSCC has two main subtypes: human …

Prevalence of EGFR tyrosine kinase domain mutations in head and neck squamous cell carcinoma: cohort study and systematic review

C Perisanidis - In vivo, 2017 - iv.iiarjournals.org
Background: Mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase
domain (TKD) are associated with response and resistance to targeted therapy. The EGFR …

Nanobody targeting of epidermal growth factor receptor (EGFR) ectodomain variants overcomes resistance to therapeutic EGFR antibodies

J Tintelnot, N Baum, C Schultheiß, F Braig… - Molecular Cancer …, 2019 - AACR
Epidermal growth factor receptor (EGFR) ectodomain variants mediating primary resistance
or secondary treatment failure in cancer patients treated with cetuximab or panitumumab …

[HTML][HTML] Role of EGFR gene polymorphisms in oral squamous cell carcinoma patients of Southeast Iran: A case-control study

S Saravani, N Parsamanesh… - Caspian Journal of …, 2020 - ncbi.nlm.nih.gov
Background: The decisive etiology of oral squamous cell carcinoma (OSCC) is still
ambiguous, but we recognize the contribution of genetic aberration and environmental …

Analysis of polymorphisms in EGF, EGFR and HER2 genes in pancreatic neuroendocrine tumors (PNETs)

S Marinović, MC Berković, V Zjačić-Rotkvić… - Cancer Genetics, 2022 - Elsevier
Abstract Objectives Pancreatic neuroendocrine tumors (NETs) are rare and account for
about 7% of all cancers occurring in the pancreas. The epidermal growth factor family of …